ClinicalTrials.gg
CompletedNCT00718887Updated Feb 11, 2013Results posted

Suboptimal Responders to Adefovir Switching to Entecavir

A Phase 4 interventional study of Entecavir and Adefovir/Entecavir in Hepatitis B, Chronic, sponsored by Bristol-Myers Squibb. Completed at 8 sites in China. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2013-02-11.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Enrollment
16th of 61
228 · median 109
Started
2008
with 7 others
Phase 4
33 of 64
2 open now
Registered
17th of 64
by date
Lead sponsor
19 of 64
Bristol-Myers Squibb

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 16th largest by enrollment of the 61 interventional ones that give a count, is one of 8 that started in 2008, is one of 33 in phase 4, and was the 17th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

Switching to Entecavir will result in superior antiviral efficacy as compared to continuing with Adefovir in patients with a suboptimal response to Adefovir

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic infection with virus (HBV)(detectable hepatitis B surface antibody (HBsAg) at screening and at least 24 weeks prior to screening, or detectable HBsAg for \<24 weeks and negative for immunoglobulin M core antibody)
  • Documentation of hepatitis B e antigen (HBeAg) positive or negative status
  • Naive to nucleoside/nucleotide analogues, with the exception of adefovir
  • Suboptimal response to adefovir treatment
  • No lamivudine/telbivudine, entecavir, or adefovir resistance-associated substitutions at screening
  • Male or female gender, aged 16 years and older
  • Compensated liver function
  • Serum level \<10* at screening

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding
  • Evidence of decompensated cirrhosis
  • Coinfection with , virus, or hepatitis D virus
  • Recent history of pancreatitis (within 24 weeks prior to the first dose of study medication)
  • Chronic renal insufficiency, defined as a \<50 mL/min
  • Current abuse of illegal drugs or alcohol, sufficient in the investigator's opinion to prevent adequate compliance with study therapy or to increase the risk of hepatotoxicity or pancreatitis
  • Other serious medical conditions that might preclude completion of this study or that require chronic administration of prohibited medications
  • Serum creatinine level >1.5 mg/dL; level \<10.0 g/dL; count \<70,000/mm\^3; \<1500 cells/mm\^3; serum alpha fetoprotein level >100 ng/mL
  • Except adefovir, any prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against (eg, lamivudine, entecavir), or any other experimental anti-HBV antiviral, or any China Traditional Medicine
  • Therapy with interferon, thymosin alpha, or other immunostimulators within 24 weeks of randomization
  • Required chronic administration of medications that cause , that are associated with a high risk of nephrotoxicity or hepatotoxicity, or that affect renal excretion.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
228 participants (actual)

Study arms

  • Experimental
    Entecavir, 0.5 mg QD

    Drug: Entecavir

  • Other
    Adefovir, 10 mg QD/Entecavir, 0.5 mg QD

    Control

    Drug: Adefovir/Entecavir

Interventions

  • Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks

    Also known as: Baraclude, BMS-200475

  • DrugAdefovir/Entecavir

    Drug pages: Adefovir · Entecavir

    Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks

    Also known as: Baraclude, BMS-200475

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved a Hepatitis B Virus (HBV) DNA Level <50 IU/mL at Week 12 by Polymerase Chain Reaction Testing

    HBV DNA Level \<50 IU/mL=approximately 300 copies/mL.

    Time frame: At Week 12 from Day 1

Secondary outcomes

  1. Percentage of Participants Who Achieved an HBV DNA Level <50 IU/mL at Week 48 by Polymerase Chain Reaction Testing

    HBV=hepatitis B virus. HBV DNA Level \<50 IU/mL=approximately 300 copies/mL.

    Time frame: At Week 48 from Day 1

  2. Mean log10 Reduction From Baseline in Serum HBV DNA Level by Polymerase Chain Reaction Testing

    HBV=hepatitis B virus

    Time frame: At Weeks 12 and 48 from Day 1

  3. Percentage of Participants Who Achieved Normalization of Alanine Aminotransferase (ALT)

    ULN=upper limit of normal. ALT normalization= ≤1\*ULN, among participants with baseline ALT \>1\*ULN

    Time frame: At Weeks 12 and 48 from Day 1

  4. Percentage of Participants With Loss of Hepatitis B e Antigen (HBeAg) and Hepatitis B e (HBe) Seroconversion

    Time frame: At Weeks 12 and 48 from Day 1

  5. Number of Participants With Hepatitis B s Surface Antibody (HBsAG) Loss and HBsAG Seroconversion

    Time frame: At Weeks 12 and 48 from Day 1

  6. Number of Participants With Genotypic Resistance to Entecavir

    Time frame: At Week 48 from Day 1

  7. Number of Participants With Adverse Events, Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, Death as Outcome, Discontinuations Due to AEs, and Abnormalities in Laboratory Test Results (LTR) Leading to Discontinuation

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study drug.

    Time frame: Continually from Day 1 through Week 48, and through 24-week follow-up period

  8. Percentage of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results

    Hematology testing assessed levels of hemoglobin, white blood cells, platelets, neutrophils, international normalized ration, red blood cells, lymphocytes, and monocytes.

    Time frame: Day 1 through Week 48

07

Results

Posted Feb 11, 2013

Participant flow

Participant flow — Overall Study
MilestoneEntecavir, 0.5 mg QDAdefovir, 10 mg QD/Entecavir, 0.5 mg QD
Started8977
Completed8468
Not completed59
Withdrew: Withdrawal by subject32
Withdrew: Not identified27

Outcome measures

PrimaryPercentage of Participants Who Achieved a Hepatitis B Virus (HBV) DNA Level <50 IU/mL at Week 12 by Polymerase Chain Reaction Testing

HBV DNA Level \<50 IU/mL=approximately 300 copies/mL.

Time frame:
At Week 12 from Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a Hepatitis B Virus (HBV) DNA Level <50 IU/mL at Week 12 by Polymerase Chain Reaction Testing
Percentage of participantsEntecavir, 0.5 mg QDAdefovir, 10 mg QD
Percentage of Participants Who Achieved a Hepatitis B Virus (HBV) DNA Level <50 IU/mL at Week 12 by Polymerase Chain Reaction Testing5.60.0
SecondaryPercentage of Participants Who Achieved an HBV DNA Level <50 IU/mL at Week 48 by Polymerase Chain Reaction Testing

HBV=hepatitis B virus. HBV DNA Level \<50 IU/mL=approximately 300 copies/mL.

Time frame:
At Week 48 from Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved an HBV DNA Level <50 IU/mL at Week 48 by Polymerase Chain Reaction Testing
Percentage of participantsEntecavir, 0.5 mg QDAdefovir, 10 mg QD/Entecavir, 0.5 mg QD
Percentage of Participants Who Achieved an HBV DNA Level <50 IU/mL at Week 48 by Polymerase Chain Reaction Testing31.528.6
SecondaryMean log10 Reduction From Baseline in Serum HBV DNA Level by Polymerase Chain Reaction Testing

HBV=hepatitis B virus

Time frame:
At Weeks 12 and 48 from Day 1
Reported as:
Mean · log10 IU/mL
Mean log10 Reduction From Baseline in Serum HBV DNA Level by Polymerase Chain Reaction Testing
log10 IU/mLEntecavir, 0.5 mg QDAdefovir, 10 mg QD/Entecavir, 0.5 mg QD
Week 12 (n=88, 77)-2.5 ± 1.2-0.2 ± 1.1
Week 48 (n=87, 71)-3.3 ± 1.5-3.2 ± 1.3
SecondaryPercentage of Participants Who Achieved Normalization of Alanine Aminotransferase (ALT)

ULN=upper limit of normal. ALT normalization= ≤1\*ULN, among participants with baseline ALT \>1\*ULN

Time frame:
At Weeks 12 and 48 from Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Normalization of Alanine Aminotransferase (ALT)
Percentage of participantsEntecavir, 0.5 mg QDAdeforvi, 10 mg QD/Entecavir, 0.5 mg QD
Week 12 (n=51, 36)31.422.2
Week 48 (n=51, 36)60.847.2
SecondaryPercentage of Participants With Loss of Hepatitis B e Antigen (HBeAg) and Hepatitis B e (HBe) Seroconversion
Time frame:
At Weeks 12 and 48 from Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Loss of Hepatitis B e Antigen (HBeAg) and Hepatitis B e (HBe) Seroconversion
Percentage of participantsEntecavir, 0.5 mg QDAdefovir, 10 mg QD/Entecavir, 10 mg QD
HBeAG loss Week 12 (n=79, 72)3.86.9
HBeAG loss Week 48 (n=79, 72)7.66.9
HBe seroconversion Week 12 (n=79, 72)2.51.45
HBe seroconversion Week 48 (n=79, 72)3.82.8
SecondaryNumber of Participants With Hepatitis B s Surface Antibody (HBsAG) Loss and HBsAG Seroconversion
Time frame:
At Weeks 12 and 48 from Day 1
Reported as:
Number · Participants
Number of Participants With Hepatitis B s Surface Antibody (HBsAG) Loss and HBsAG Seroconversion
ParticipantsEntecavir, 0.5 mg QDAdefovir, 10 mg QD/Entecavir, 0.5 mg QD
Week 12 HBsAg loss00
Week 48 HBsAg loss00
Week 12 HBsAg seroconversion00
Week 48 HBsAg seroconversion00
SecondaryNumber of Participants With Genotypic Resistance to Entecavir
Time frame:
At Week 48 from Day 1
Reported as:
Number · Participants
Number of Participants With Genotypic Resistance to Entecavir
ParticipantsEntecavir, 0.5 mg QDAdefovir, 10 mg QD/Entecavir, 0.5 mg QD
At baseline00
Week 4800
SecondaryNumber of Participants With Adverse Events, Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, Death as Outcome, Discontinuations Due to AEs, and Abnormalities in Laboratory Test Results (LTR) Leading to Discontinuation

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study drug.

Time frame:
Continually from Day 1 through Week 48, and through 24-week follow-up period
Reported as:
Number · Participants
Number of Participants With Adverse Events, Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, Death as Outcome, Discontinuations Due to AEs, and Abnormalities in Laboratory Test Results (LTR) Leading to Discontinuation
ParticipantsEntecavir, 0.5 mg QDAdefovir, 10 mg QD/Entecavir, 0.5 mg QD
All AEs167
Treatment-related AEs00
SAEs10
Treatment-related SAEs00
Death00
AEs leading to discontinuation10
Abnormalities in LTR leading to discontinuation00
SecondaryPercentage of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results

Hematology testing assessed levels of hemoglobin, white blood cells, platelets, neutrophils, international normalized ration, red blood cells, lymphocytes, and monocytes.

Time frame:
Day 1 through Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results
Percentage of participantsEntecavir, 0.5 mg QDAdefovir, 10 mg QD
Alanine aminotransferase95.2
Aspartate aminotransferase2.20
Hyperkalemia01
Hematology00

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Entecavir, 0.5 mg QD—1/89 (1.1%)8/89 (9%)
Adefovir, 10 mg QD/Entecavir, 0.5 mg QD—0/77 (0%)9/77 (11.7%)
Most frequent serious events
Most frequent serious events
EventEntecavir, 0.5 mg QDAdefovir, 10 mg QD/Entecavir, 0.5 mg QD
Drug hepatitisHepatobiliary disorders1/890/77
Most frequent other events
Most frequent other events
EventEntecavir, 0.5 mg QDAdefovir, 10 mg QD/Entecavir, 0.5 mg QD
Alanine aminotransferase increasedInvestigations8/899/77
Aspartate aminotransferase increasedInvestigations5/890/77

Baseline characteristics

Age Continuous
Age Continuous(Years)Entecavir, 0.5 mg QDAdefovir, 10 mg QD/Entecavir, 0.5 mg QDTotal
Median32.6 (16.9 to 62.4)34.1 (18.9 to 63.1)33.4 (16.9 to 63.1)
Sex: Female, Male
Sex: Female, Male(Participants)Entecavir, 0.5 mg QDAdefovir, 10 mg QD/Entecavir, 0.5 mg QDTotal
Female141024
Male7567142
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Entecavir, 0.5 mg QDAdefovir, 10 mg QD/Entecavir, 0.5 mg QDTotal
Asian8977166
Other000
08

Study locations

8 sites
  • Local Institution
    Beijing, Beijing 100011, China
  • Local Institution
    Guiyang, Guizhou 550004, China
  • Local Institution
    Nanjing, Jiangsu 210002, China
  • Local Institution
    Nanchang, Jiangxi 330006, China
  • Local Institution
    Changchun, Jilin 130021, China
  • Local Institution
    Shenyang, Liaoning 110004, China
  • Local Institution
    Shanghai, Shanghai 200235, China
  • Local Institution
    Shanghai, Shanghai, China
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Dec 2009 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2008
First posted
Jul 21, 2008
Start
Jul 2008
Primary completionActual
Dec 2009
CompletionActual
Jan 2011
Results first posted
Feb 11, 2013
Last update
Feb 11, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00718887
Responsible party
Sponsor
First posted
Jul 21, 2008
Start date
Jul 2008
Primary completion
Dec 2009
Completion
Jan 2011
Results posted
Feb 11, 2013
Last update
Feb 11, 2013

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entecavir

Start the discussion